satralizumab   Click here for help

GtoPdb Ligand ID: 9093

Synonyms: Enspryng® | RG-6168 | RG6168 | SA-237 | SA237 | sapelizumab (deprecated INN) | satralizumab-mwge
Approved drug Immunopharmacology Ligand
satralizumab is an approved drug (Canada, Japan and FDA (2020), EMA (2021))
Compound class: Antibody
Comment: Satralizumab (previously referred to using the replaced INN sapelizumab) is an investigational humanized monoclonal antibody targeting the IL-6 receptor, with immunomodulatory potential. This antibody is an improved version of tocilizumab, with enhanced antigen-neutralizing ability and pharmacokinetics suitable for less frequent administration [2].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide BLAST searches reveal identical matches between the heavy and light chain sequences as annotated in IMGT and SEQ IDs 26 and 29 respectively claimed in patent US8562991 [2]. This matches satralizumab to the Fv4-M73 construct in the patent.
Click here for help
Classification Click here for help
Compound class Antibody
Approved drug? Yes. Canada (2020)  |  FDA (2020)  |  Japan (2020)  |  EMA (2021)
International Nonproprietary Names Click here for help
INN number INN
10065 satralizumab
Synonyms Click here for help
Enspryng® | RG-6168 | RG6168 | SA-237 | SA237 | sapelizumab (deprecated INN) | satralizumab-mwge
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 586
Other databases
GtoPdb PubChem SID 315661178
Search PubMed clinical trials satralizumab
Search PubMed titles satralizumab
Search PubMed titles/abstracts satralizumab